Clinical Trial Update: A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial evaluating IBI302 in patients with age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• IBI302

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 1 | Status: COMPLETED